Active Biotech (ACTI) investor relations material

Strategic focus and pipeline overview

• Refocused on specialist disease areas with large unmet medical needs, particularly in oncology and inflammation.

• Key assets include tasquinimod (hematological malignancies) and laquinimod (inflammatory eye disorders), both with ongoing or recently completed clinical programs.

• Tasquinimod is prioritized for myelofibrosis, with Orphan Drug Designation (ODD) granted by the FDA in 2022.

• Laquinimod development continues in partnership, targeting non-infectious uveitis and other eye disorders.

• Strong partnerships with leading academic centers and a robust international network of experts.

Tasquinimod clinical development and market potential

• Two ongoing Phase Ib/II trials in myelofibrosis, with interim results expected in 2026 and final results in 2027.

• Preclinical data show tasquinimod improves myelofibrosis symptoms and synergizes with JAK and BET inhibitors.

• Clinical benefit rate of 47% observed in heavily pretreated multiple myeloma patients in combination with IRd.

• Orphan Drug Designation in the US for both myelofibrosis and multiple myeloma, with patent protection until at least 2044.

• Myelofibrosis and myelodysplastic syndrome markets represent multi-billion dollar opportunities.

Laquinimod for eye disorders

• First-in-class immunomodulator for non-anterior non-infectious uveitis, with a completed Phase I ocular biodistribution study.

• Demonstrated safety, tolerability, and effective ocular distribution in hydrogel eye drop formulation.

• Preclinical and clinical data support both oral and topical administration, with patent protection through 2042.

• Addresses significant unmet need as current treatments rely on corticosteroids and immunosuppressants, which have limitations.

• Projected sales for non-infectious uveitis therapies in key markets to reach USD 1.5 billion by 2033.